Myocardial infarction (MI) is one of the leading causes of death in the world. Early myocardial reperfusion improves acute MI survival. Bioflavonoid quercetin is known to have antioxidant, anti-inflammatory, and anti-proliferative properties. The presented pilot study aims to investigate the cardioprotective effect of quercetin on infarct size limiting in ST-segment elevation myocardial infarction (STEMI) patients. Patients (n=143) with the first anterior STEMI within 6 hours from symptoms onset were included in the open-label multicenter pilot study. Patients were randomized either to quercetin group (n=70) in addition to standard treatment or recommended therapy alone (control group, n=73). Quercetin infusions were initiated before reperfusion and repeated during the next 5 days. The infarct size assessed by CK-MB AUC was the primary study outcome. The study arms matched well regarding demographics, time to admission, and main clinical data. The median early CK-MB AUC was significantly lower in quercetin group than in controls (8036±7594 vs 11219±8146 U×1h/L, p=0.015). Intravenous quercetin was associated with less reperfusion-induced intramyocardial hemorrhage by Cardiac Magnetic Resonance on Day 3 (11.1% of patients in quercetin group vs 53.3% of patients in control group, p<0.024). There were no significant differences in left ventricle ejection fraction (LVEF) and LV remodeling indicators. Our pilot study is the first to demonstrate novel insight into ischemia/reperfusion damage in STEMI patients. The addition of quercetin to standard STEMI therapy limits infarct size and prevents intramyocardial hemorrhage after the first anterior STEMI. Further research will be necessary to both validate and expand upon these findings.